Group 1 - First Community (FCCO) shares have increased by 5.1% over the past four weeks, closing at $23.70, with a mean price target of $29.67 indicating a potential upside of 25.2% [1] - The average price targets range from a low of $29 to a high of $30, with a standard deviation of $0.58, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about FCCO's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.1% over the past month, with one estimate rising and no negative revisions [12] - FCCO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Shares of FormFactor (FORM) have gained 0.9% over the past four weeks to close the last trading session at $28.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $42 indicates a potential upside of 47.2%.The average comprises nine short-term price targets ranging from a low of $26 to a high of $52, with a standard deviation of $8.83. While the lowest estimate indicates a declin ...

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $8.48, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.79 indicates a 392.8% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $27.61. While the lowest estimate of $9 indicates a 6.1% increase from the current price level, the most optimistic a ...

Core Viewpoint - AngioDynamics (ANGO) shares have seen a 1.1% increase over the past four weeks, closing at $9.60, with analysts suggesting a potential upside of 63.2% based on a mean price target of $15.67 [1] Price Targets - The average price target consists of three estimates ranging from a low of $15 to a high of $16, with a standard deviation of $0.58, indicating a strong consensus among analysts [2] - The lowest estimate suggests a 56.3% increase, while the highest indicates a 66.7% upside [2] Analyst Sentiment - Analysts show strong agreement regarding ANGO's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with stock price movements, suggesting that this could be a reliable indicator of future performance [11] Earnings Estimates - Over the last 30 days, three earnings estimates for ANGO have been revised upward, with no negative revisions, leading to a 22.5% increase in the Zacks Consensus Estimate [12] - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Core Viewpoint - Dream Finders Homes Inc. (DFH) shows potential for upside with a mean price target of $29.50, indicating a 29.9% upside from the current price of $22.71 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.44, suggesting variability among analysts [2] - The lowest estimate of $26 indicates a 14.5% increase, while the highest estimate of $34.50 suggests a potential surge of 51.9% [2] - A low standard deviation indicates strong agreement among analysts regarding price movement direction [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about DFH's earnings prospects, as evidenced by higher EPS estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 1.1% over the past month, with one estimate rising and no negative revisions [12] - DFH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Brookfield Renewable Energy Partners (BEP) has seen a 1.4% increase in share price over the past four weeks, closing at $22.57, with a potential upside of 32.1% based on Wall Street analysts' mean price target of $29.81 [1] Price Targets and Analyst Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $2.54, indicating variability among analysts; the lowest estimate is $23 (1.9% increase), while the highest is $33 (46.2% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about BEP's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1.5% over the past month, with one estimate increasing and no negative revisions [12] - BEP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13]

Pagaya Technologies Ltd. (PGY) closed the last trading session at $11.21, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.56 indicates a 101.3% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $7.24. While the lowest estimate of $12.50 indicates an 11.5% increase from the current price level, the most optimisti ...

Core Viewpoint - Enlight Renewable Energy Ltd. (ENLT) shows potential for upside with a mean price target of $20.40, indicating a 27.8% increase from the current price of $15.96 [1] Price Targets and Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.30, suggesting variability among analysts [2] - The lowest estimate of $18 indicates a 12.8% increase, while the highest estimate suggests a 44.1% surge to $23 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about ENLT's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 0.4% due to one upward revision [12] - ENLT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Knightscope, Inc. (KSCP) has shown a significant price increase of 24.4% over the past four weeks, with a mean price target of $17.67 indicating a potential upside of 250.6% from the current price of $5.04 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $12.50, where the lowest estimate of $9 suggests a 78.6% increase, and the highest estimate of $32 indicates a potential surge of 534.9% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about KSCP's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 6.9% rise in the Zacks Consensus Estimate for the current year [12] - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Core Viewpoint - Coya Therapeutics, Inc. (COYA) shows significant upside potential with a mean price target of $16.25, indicating a 144.7% increase from its current price of $6.64 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.06, suggesting variability among analysts; the lowest estimate of $14 indicates an 110.8% increase, while the highest target is $18, representing a 171.1% increase [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about COYA's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 7.8% rise in the Zacks Consensus Estimate for the current year [12] - COYA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]